🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 00507W206 (prev. 00507W107 )
- Market Cap
- Small Cap
Business: Actinium Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells both safely and effectively. Actinium is currently progressing three drug candidates in clinical trials.
Notes: Aug. 10, 2020 -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its Board of Directors approved a 1-for-30 reverse split of its issued and outstanding common stock that will become effective after trading closes on August 10, 2020. Trading of the Company common stock will begin on a split-adjusted basis when markets open on August 11, 2020. The common stock will continue to trade on the NYSE American under the ticker symbol "ATNM," although a new CUSIP number 00507W206 has been assigned as a result of the reverse stock split.
Company Contact
- CEO
- Sandesh Seth
- CFO
- Steve O'Loughlin
- Headquarters
- 275 Madison Ave, 7th Floor New York, NY 10016
- Phone
- 646-677-3870
- Investor Relations
- Hans Vitzthum · 617-535-7743 · Hans@LifeSciAdvisors.com